Pulse Biosciences (PLSE) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
34 figures withheld by our checks. Each blank figure names its reason.
28.0mn → 68.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
▲152% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
$0.0M returned vs $−54.4M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
-20795¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross -38.8% → -54.0%. Net margin -20794.6% is below the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,494.0 | 350.0 | 0.0 | 0.0 | 700.0 | 1,418.0 | — | −29.5% |
Cost of revenue | 1,094.0 | 539.0 | 0.0 | 0.0 | 11,944.0 | 1,968.0 | — | −27.7% |
Gross profit | 400.0 | −189.0 | —A | —A | −11,244.0 | −550.0 | — | — |
Research & development | 57,341.0 | 44,721.0 | 32,336.0 | 27,797.0 | 20,839.0 | 28,640.0 | ▲38.3% | +11.8% |
Selling, general & admin | 30,026.0 | 32,029.0 | 23,921.0 | 15,777.0 | 13,955.0 | 19,073.0 | ▲33.9% | +13.8% |
Total operating expenses | 87,367.0 | 76,750.0 | 56,257.0 | 43,574.0 | 46,813.0 | 62,464.0 | ▲36.4% | +5.3% |
Operating incomefeeds ROC rank | −86,967.0 | −76,939.0 | −56,257.0 | −43,574.0 | −58,057.0 | −63,014.0 | ▼36.8% | — |
Other income, net | 3,245.0 | 4,158.0 | 2,672.0 | 1,364.0 | −448.0 | −646.0 | — | — |
Pretax income | −83,722.0 | −72,781.0 | −53,585.0 | −42,210.0 | −58,505.0 | −63,660.0 | ▼35.8% | — |
Income tax | — | — | — | 0.0 | 0.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −83,722.0 | −72,781.0 | −53,585.0 | −42,210.0 | −58,505.0 | −63,660.0 | ▼35.8% | — |
| Per share | ||||||||
Diluted shares (mn) | 73.55 | 67.99 | 67.27 | 55.23 | 37.59 | 27.96 | ▲1.1% | +24.9% |
| Margins | ||||||||
Gross margin | 26.8% | −54.0% | —A | —A | −1606.3% | −38.8% | — | — |
Operating margin | −5821.1% | −21982.6% | — | — | −8293.9% | −4443.9% | — | — |
Net margin | −5603.9% | −20794.6% | — | — | −8357.9% | −4489.4% | — | — |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Pulse Biosciences' net income?
Pulse Biosciences reported net income of −$72,781.0K in fiscal 2025, a net margin of −20794.6%.

